Global "Genital Dysfunction Drugs Market" Expected to reach a high CAGR of 5.7% during the forecasting period 2022 - 2029
Genital dysfunction, also known as erectile dysfunction (ED) is the inability to maintain sufficient for satisfactory sexual performance.
Genital Dysfunction can also be referred to as impotence. Occasional ED is not uncommon, and most men experience it during times of stress.
Frequent ED can be a sign of health-related issues which need treatment. The available drugs for the treatment of erectile dysfunction are branded and generic drugs.
The possible causes for ED are affected by both emotional and physical disorders. Some common reasons are cardiovascular disease, diabetes, hypertension, hyperlipidemia, cancer or cancer-related surgery, injuries, obesity, age, stress and anxiety, drug use, alcohol use.
ED can be caused by any of these factors. A number of large multinational studies have estimated the prevalence of ED in young men to be as high as 30%.
The growth of the genital dysfunction drug market is driven by the increasing number of men suffering from ED. It is a common medical condition primarily affecting men above 40 years of age, thereby the rise in aging population is another factor driving the market.
Other factors responsible for the growth of the market are their sedentary lifestyle, stress, hypertension, anxiety, and chronic diseases.
Physical and psychological issues, stress, and mental health concerns may worsen the problem of ED.
However, the availability of counterfeit drugs, patent expiry of many blockbuster drugs, and increasing manufactures of generic medicines in the market may hinder the genital dysfunction drugs market.
The genital dysfunction drugs market, by the drug, is segmented into Viagra, Cialis, Levitra, Stendra, Zydena, and other drugs. Viagra holds the most significant share as it is one of the most widely distributed products worldwide.
However, its patent expires by 2019 in the U.S., which may hinder its market growth in the future.
By mode of administration, the genital dysfunction drugs market is categorized into oral medications, topical medications, injections, and others.
The most significant segment is the oral medication segment as the first line of treatment or medication for ED comprises of oral medication.
By the distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others.
The online pharmacies share is expected to dominate the market and be the fastest-growing share as well. It is mainly due to anonymity that is provided by online retailers as a significant stigma around ED still exists in many places and people.
By Geography, North America dominates the market for genital dysfunction drugs. It is mainly driven by the availability of most recognized brands like Viagra, and Levitra/Staxyn.
But with the patent expiration of these branded drugs looming shortly, it may affect the regional market. However, with the broad base of the patient population and the presence of significant medical companies and technological advancement, the demand for efficient supplies is increasing in this region keeping its dominance over this market share.
Europe holds the second-largest share of the market for ED drugs region-wise. This mainly is attributed to the higher spending of the local critical players on R&D activities, and also Europe has high healthcare investments and government funding. The development in emerging areas like orphan drugs will likely promote the demand for regulatory expertise, in turn, contributing to the growth of ED drugs market in this region.
The market for genital dysfunction drugs is moderately competitive, with market players are actively investing in research for developing innovative products.
Several companies have adopted merger and acquisitions policies and collaborations to help them to stand out as strong competitors in the market and also expand their sales in the global ED drug market.
In addition to mergers and collaborations activities, post-patent expiration, and geographic expansion are likely to keep the market competitive. Some critical competitors of the genital dysfunction market are Pfizer, Bayer AG, and Eli Lilly & Co.
American pharmaceutical company, Pfizer in 2019 lost patent protection on its blockbuster genital dysfunction drug Viagra, among others, pain killer Lyrica faces similar competition from generic drug-makers.
In May 2017, Lupin Ltd. launched Cialis (ED drug) by a licensing agreement with Eli Lilly. In this agreement, Eli Lilly was responsible for manufacturing and importing the product to India.
December 2017 – Pfizer, the manufacturer of Viagra, settled trade disputes with Teva Pharmaceutical, a generic manufacturer. This agreement allowed Teva to start selling generic Viagra (sildenafil).
Drugs for Vulvovaginal Candidiasis Market